Comparative study of COPD double therapy versus triple therapy: an EGB data analysis

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/26917
• EU PAS number:
  EUPAS26916
• Study ID:
  26917
• Official title and acronym:
  Comparative study of COPD double therapy versus triple therapy: an EGB data analysis
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  The primary objective of this study was to define the potential added value of triple therapy compared with double therapy (fixed or free combinations) in real use in COPD patients, in terms of exacerbations, healthcare consumption, related costs and persistence.
• Study status:
  Finalised

Research institution and networks

Institutions

PharmacoEpidemiology Unit (PELyon), Claude Bernard Lyon 1 University

France

Study timelines

Date when funding contract was signed

Actual: 02/09/2016

Study start date

Actual: 10/01/2017

Date of final study report

Actual: 26/07/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Chiesi

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable